zoledronic acid has been researched along with Hyperparathyroidism, Secondary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cipriani, C; Clementelli, C; Colangelo, L; Fassino, V; Manai, R; Minisola, S; Nieddu, L; Pepe, J | 1 |
| Anastasilakis, AD; Arsos, G; Efstathiadou, Z; Kita, M; Litsas, I; Moralidis, E; Papatheodorou, A; Polyzos, SA; Terpos, E | 1 |
| Berruti, A; Buttigliero, C; Coleman, RE; Cook, R; Lee, KA; Lipton, A; Saad, F; Smith, MR; Tampellini, M | 1 |
| Angus, PW; Byth, K; Crawford, BA; Handelsman, DJ; Kam, C; McCaughan, GW; Pavlovic, J | 1 |
2 trial(s) available for zoledronic acid and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Imidazoles; Male; Middle Aged; Multivariate Analysis; Parathyroid Hormone; Prognosis; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2012 |
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Hypocalcemia; Imidazoles; Infusions, Intravenous; Liver Failure; Liver Transplantation; Osteoporosis; Parathyroid Hormone; Zoledronic Acid | 2006 |
2 other study(ies) available for zoledronic acid and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Calcium; Chemokine CCL2; Diphosphonates; Female; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Imidazoles; Infusions, Intravenous; Interleukin-18; Male; Osteoporosis; Pilot Projects; Renal Elimination; Zoledronic Acid | 2017 |
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
Topics: Adult; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Monitoring; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Imidazoles; Osteitis Deformans; Radiography; Zoledronic Acid | 2010 |